

Mountain View Pharmaceuticals Elects Raymond J. Land to Its Board of Directors

Menlo Park, CA, May 4, 2005 – At the Company's Annual Meeting on April 18, 2005, the shareholders of Mountain View Pharmaceuticals, Inc. (MVP) elected Raymond J. Land as a new member of its Board of Directors.

Raymond J. Land, C.P.A., has been appointed Senior Vice President and Chief Financial Officer of Orchid BioSciences, Inc. (ORCH; Princeton, NJ) effective June 6, 2005. Since 1997, he has been the Senior Vice President and Chief Financial Officer of Genencor International, Inc. (GCOR; Palo Alto, CA), which was recently acquired by the global company Danisco. Prior to joining Genencor, he was a Senior Vice President and Chief Financial Officer of West Pharmaceutical Services (WST; Lionville, PA), Vice President, General Manager and Vice President, Corporate Controller at Campbell Soup Company (CPB; Camden, NJ) and an audit manager at Coopers & Lybrand in Philadelphia, PA. In 1972, he received a B.B.A. from Temple University with a double major in Finance and Accounting.

In welcoming Mr. Land's election at the Annual Meeting, Mr. Jean M. Bellin, Chief Executive Officer of MVP, stated: "Ray's general and financial management experience, including corporate strategic alliances and managing large public enterprises, will be invaluable to MVP and will provide us with additional insights and guidance as we continue to expand our business."

About Mountain View Pharmaceuticals, Inc. (MVP)

Founded in November 1995, MVP is a private company engaged in the research and development of long-acting polymer conjugates of therapeutic proteins.

MVP's proprietary technology, referred to as "Rational PEGylationSM," is a next-generation strategy for attaching poly(ethylene glycol) or PEG to therapeutic proteins to enhance their safety, efficacy and duration of action. Rational PEGylationSM involves the selective coupling of PEG to sites that are remote from the functional regions of proteins. This strategy provides an improved yield of nearly homogeneous preparations that function much more effectively than the products of first-generation PEGylation.

MVP's combinatorial approach and unique expertise enable the rapid and cost-effective optimization of the chemistry of attachment, as well as the size, structure and the number of strands of PEG. MVP's novel PEGylation technology is broadly applicable to enzymes, polypeptide hormones, growth factors and cytokines, such as interferons, as well as to therapeutic viruses.

In addition to the site-selective coupling of PEG, MVP has invented a proprietary polymer with an improved immunologic profile, trademarked PharmaPEG[®].

MVP's technology is protected by a strong intellectual property estate of issued US patents, corresponding issued patents in Europe and other countries, and seven families of pending patent applications in the US and up to 60 other countries.

CONTACT: Mark G. P. Saifer, Ph.D.
saifer@mvpharm.com
Mountain View Pharmaceuticals, Inc.
3475-S Edison Way
Menlo Park, California 94025-1821
Phone: 650-365-5515
Fax: 650-365-5525
www.mvpharm.com

SOURCE: Mountain View Pharmaceuticals, Inc.